PSS42 - SECUKINUMAB SIGNIFICANTLY REDUCES PSORIASIS-RELATED WORK IMPAIRMENT AND INDIRECT COSTS COMPARED TO USTEKINUMAB AND ETANERCEPT IN MOROCCO
Abstract
Authors
A. Kooli C. Graham N. Scheuer I. Gilloteau L. Miles B. Sherif D. McBride